PubMed Health⌕ Search

PubMed · 9173717

[Transmyocardial revascularization].

Abstract

Transmyocardial laser revascularization refers to the perfusion of the reptilian heart with its large ventriculo-myocardial channels and to well-known ventriculo-coronary connections in congenital heart defects. By a high energy CO2-laser transmural channels can be created at a beating heart and may, by connecting to the intramyocardial capillary network or by inducing a neocapillarization, improve the blood supply to the ischemic myocardium. This indirect method of revascularization is indicated in symptomatic patients with diffuse coronary heart disease, not accessible by conventional methods like PTCA or coronary bypass surgery. Worldwide, this new kind of operation has already been performed in some 100 intractable patients. In our hospital 79 patients have been treated with this new technique, 37 of them in conjunction with conventional bypass surgery. The majority of those patients had already undergone one or two bypass operations. The perioperative mortality was 11.4% including three non cardiac events. Postoperative follow-up after 3 and 6 months showed among the reinvestigated patients a significant improvement concerning angina- (CCS) and clinical classification (NYHA). Scintigraphy after the same time period revealed an improvement of myocardial perfusion in 50% of the reinvestigated patients. These results as well as the international reports demonstrate a clinical efficacy of this new therapeutic approach in a selected group of severely diseased patients. Further objective data and also experimental studies have to confirm the role of this new method in the treatment of diffuse coronary heart disease.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Moosdorf. 1997. [Transmyocardial revascularization].. https://pubmed.ncbi.nlm.nih.gov/9173717/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗